Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Goodwill (2017 - 2019)

Aclaris Therapeutics has reported Goodwill over the past 3 years, most recently at $18.5 million for Q4 2019.

  • Quarterly results put Goodwill at $18.5 million for Q4 2019, changed 0.0% from a year ago — trailing twelve months through Dec 2019 was $18.5 million (changed 0.0% YoY), and the annual figure for FY2019 was $18.5 million, changed 0.0%.
  • Goodwill for Q4 2019 was $18.5 million at Aclaris Therapeutics, roughly flat from $18.5 million in the prior quarter.
  • Over the last five years, Goodwill for ACRS hit a ceiling of $18.5 million in Q3 2017 and a floor of $18.5 million in Q3 2017.
  • Median Goodwill over the past 3 years was $18.5 million (2017), compared with a mean of $18.5 million.
  • Peak annual rise in Goodwill hit 0.0% in 2018, while the deepest fall reached 0.0% in 2018.
  • Aclaris Therapeutics' Goodwill stood at $18.5 million in 2017, then changed by 0.0% to $18.5 million in 2018, then changed by 0.0% to $18.5 million in 2019.
  • The last three reported values for Goodwill were $18.5 million (Q4 2019), $18.5 million (Q1 2019), and $18.5 million (Q4 2018) per Business Quant data.